Sectors

COLL
Collegium Pharmaceutical, Inc.
24.61
2 x 18.08
2 x 31.41
bid
ask
-
0.74
2.92%
2 @ 07:56 PM
24.82 +0.21 (0.85%)
Ytd-46.85%
1y-36.57%
24.46
day range
25.39
24.46
52 week range
50.79
Open25.12Prev Close25.35Low24.46High25.39Mkt Cap762.89M
Vol1.04MAvg Vol558.21KEPS1.27P/E19.38Forward P/E4.86
Beta0.73Short Ratio11.92Inst. Own128.23%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0550-d Avg32.89200-d Avg38.601yr Est53.60

COLL News

44,493 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Freestone Grove Partners LP
defenseworld.net
44,493 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Freestone Grove Partners LP

Freestone Grove Partners LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:

BlackRock Inc. Takes $196.97 Million Position in Collegium Pharmaceutical, Inc. $COLL
defenseworld.net
BlackRock Inc. Takes $196.97 Million Position in Collegium Pharmaceutical, Inc. $COLL

BlackRock Inc. bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) during the und

A Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39
gurufocus.com
A Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39

On August 27, 2026, Collegium Pharmaceutical Inc (COLL) shares fell 3.9% to a current price of $26.3

benzinga.com
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweig

Collegium Announces $50 Million Accelerated Share Repurchase Program
globenewswire.com
Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a

Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey
defenseworld.net
Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey

Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Avenue Therapeutics (NASDAQ: ATXI - Ge

benzinga.com
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neu

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
seekingalpha.com
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

benzinga.com
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lo

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com
Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business pe

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
zacks.com
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zac

Collegium Pharmaceutical Q2 Earnings Call Highlights
marketbeat.com
Collegium Pharmaceutical Q2 Earnings Call Highlights

Collegium Pharmaceutical NASDAQ: COLL reported second-quarter 2026 net product revenue of $199.9 mil

benzinga.com
Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000

Collegium Pharmaceutical (NASDAQ:COLL) lowers FY2026 sales outlook from $865.000 million-$895.000 mi

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
globenewswire.com
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

– Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating
seekingalpha.com
Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, l

Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
globenewswire.com
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026

STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a

Bessemer Group Inc. Acquires 31,800 Shares of Collegium Pharmaceutical, Inc. $COLL
defenseworld.net
Bessemer Group Inc. Acquires 31,800 Shares of Collegium Pharmaceutical, Inc. $COLL

Bessemer Group Inc. grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 48.

DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln
businesswire.com
DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln

BOSTON--(BUSINESS WIRE)--DivcoWest, a DivCore Capital company and national commercial real estate in

Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
globenewswire.com
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston

STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
zacks.com
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
zacks.com
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues

COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech

New Strong Buy Stocks for July 6th
zacks.com
New Strong Buy Stocks for July 6th

BBCP, KUBTY, ADM, COLL and W have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2026.

Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
zacks.com
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why

COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, s

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
zacks.com
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

benzinga.com
Collegium Pharmaceutical Affirms FY2026 Sales Guidance of $805.000M-$825.000M vs $825.757M Est

Collegium Pharmaceutical (NASDAQ:COLL) affirms FY2026 sales outlook from $805.000 million-$825.000 m

benzinga.com
Collegium Pharmaceutical Q1 Adj. EPS $1.76 Beats $1.59 Estimate, Sales $193.520M Beat $185.984M Esti

Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.76 per share which beat the

benzinga.com
HC Wainwright & Co. Reiterates Buy on Collegium Pharmaceutical, Maintains $60 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Collegium Pharmaceutical (NASDAQ:COLL)

benzinga.com
Collegium To Acquire AZSTARYS For $650M In Cash With Potential For Additional Milestone Payments Up

– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegi

Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings)
benzinga.com
Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings)

benzinga.com
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $54

Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lo

benzinga.com
Collegium Pharmaceutical Sees FY2026 Sales $805.000M-$825.000M vs $808.877M Est

Collegium Pharmaceutical (NASDAQ:COLL) sees FY2026 sales of $805.000 million-$825.000 million vs $80

Insights into Collegium Pharmaceutical Q4 Earnings
benzinga.com
Insights into Collegium Pharmaceutical Q4 Earnings

benzinga.com
Collegium Pharmaceutical Q4 Adj. EPS $2.04 Misses $2.33 Estimate, Sales $205.449M Miss $206.362M Est

Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $2.04 per share which missed t

Earnings Scheduled For February 26, 2026
benzinga.com
Earnings Scheduled For February 26, 2026

benzinga.com
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $56

Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweig

What 6 Analyst Ratings Have To Say About Collegium Pharmaceutical
benzinga.com
What 6 Analyst Ratings Have To Say About Collegium Pharmaceutical

benzinga.com
HC Wainwright & Co. Reiterates Buy on Collegium Pharmaceutical, Raises Price Target to $60

HC Wainwright & Co. analyst Brandon Folkes reiterates Collegium Pharmaceutical (NASDAQ:COLL)

benzinga.com
Needham Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $56

Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and ra

Earnings Scheduled For November 6, 2025
benzinga.com
Earnings Scheduled For November 6, 2025

benzinga.com
Earnings Scheduled For August 7, 2025

benzinga.com
Earnings Scheduled For May 8, 2025

benzinga.com
Earnings Scheduled For February 27, 2025

benzinga.com
Earnings Scheduled For February 22, 2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings

benzinga.com
Earnings Scheduled For November 7, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

benzinga.com
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big

benzinga.com
Earnings Scheduled For August 3, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

benzinga.com
Earnings Scheduled For May 4, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a

benzinga.com
Earnings Scheduled For February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnin

benzinga.com
Earnings Scheduled For November 3, 2022

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022